Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem Cells

Scripps Translational Science Institute1 site in 1 country200 target enrollmentNovember 2012

ConditionsCoronary Artery Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Coronary Artery Disease
Sponsor: Scripps Translational Science Institute
Enrollment: 200
Locations: 1
Primary Endpoint: iPSC development
Status: Enrolling By Invitation
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This research is being done to understand how changes in DNA may put people at risk for developing coronary artery disease. Stem cells will be made using cells from blood and/or skin biopsy samples. We are trying to understand which specific changes in DNA negatively impact a person's health.

Registry

clinicaltrials.gov

Start Date

November 2012

End Date

July 2030

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Scripps Translational Science Institute

Responsible Party

Principal Investigator

Eric Topol, MD

Director, Scripps Translational Science Institute

Scripps Translational Science Institute

Eligibility Criteria

Inclusion Criteria

•Previously enrolled in the CAD module of the Genebank at Scripps Clinic Registry
•Eligible to have their blood drawn
•Be reliable, cooperative and willing to comply with all protocol-specified procedures
•Able to understand and grant informed consent
•Previously enrolled in the Healthy Elderly Active Longevity (HEAL) Cohort
•Eligible to have their blood drawn
•Be reliable, cooperative and willing to comply with all protocol-specified procedures
•Able to understand and grant informed consent

Exclusion Criteria

•Unwilling or unable to grant informed consent.
•Have a significant medical condition that in the Investigator's opinion may interfere with subject's study participation.